The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary

By  

Current Cardiology Reviews, Vol. 4, Iss. 4, 2008-11 ,pp. : 293-299

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: A meta-analysis of randomized trials

By Navarese Eliano Pio   Kozinski Marek   Obonska Karolina   Margheri Massimo   Gurbel Paul Alfred   Kubica Jacek   De Luca Giuseppe  

Platelets, Vol. 23, Iss. 4, 2012-06 ,pp. : 274-281

Informa Healthcare

Access to resources Recommend Favorite

Intracoronary Injection of Glycoprotein IIb/IIIa, Abciximab, as Adjuvant Therapy in Primary Coronary Intervention

By  

Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol. 11, Iss. 2, 2013-01 ,pp. : 89-95

Bentham Science Publishers

Access to resources Recommend Favorite

A Review of Intracoronary Abciximab in Percutaneous Coronary Interventions- where are we now and where do we go from here?

By  

Recent Patents on Cardiovascular Drug Discovery, Vol. 8, Iss. 3, 2013-12 ,pp. : 192-196

Bentham Science Publishers

Access to resources Recommend Favorite

Safety of Abciximab Administration During PCI of Patients with Previous Stroke

By Deliargyris Efthymios   Upadhya Bharathi   Applegate Robert   Kontos Jimmy   Kutcher Michael   Riesmeyer Jeffrey   Sane David  

Journal of Thrombosis and Thrombolysis, Vol. 19, Iss. 3, 2005-06 ,pp. : 147-153

Springer Publishing Company

Access to resources Recommend Favorite